Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527088 | 1.00 | DHODH (0.49) | DHODHGPR119BRD4PDK1PDK2 | |
| SCHEMBL30076622 | 0.93 | KDM4E (0.53) | DHODHBRD4PDK1PDK2PDK3 | |
| SCHEMBL380901 | 0.93 | KDM4E (0.53) | DHODHBRD4PDK1PDK2PDK3 | |
| SCHEMBL23063788 | 0.90 | BRD4 (0.49) | DHODHGPR119BRD4KDM4EMPO | |
| SCHEMBL29939759 | 0.89 | CHRM4 (0.50) | DHODHGPR119BRD4NOTUMALDH1A1 | |
| SCHEMBL19689700 | 0.89 | GPR119 (0.47) | DHODHGPR119KDM4ESRD5A1NOTUM | |
| SCHEMBL1270523 | 0.89 | CHRM4 (0.50) | DHODHGPR119BRD4NOTUMALDH1A1 | |
| SCHEMBL21724876 | 0.88 | GPR119 (0.46) | DHODHGPR119BRD4KDM4ESRD5A1 | |
| SCHEMBL846218 | 0.87 | HDAC1 (0.53) | DHODHGPR119PDK1PDK2PDK3 | |
| SCHEMBL30681278 | 0.87 | GPR119 (0.45) | DHODHGPR119BRD4KDM4ESRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233962-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOD CONSEILS RECH APPLIC (FR) | 2006-03-01 | — | — | EP | claimed |
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIEQUES (S.C.R.A.S.) | 2004-09-16 | — | — | US | claimed |
| CN-1391571-A | Heterocyclic compounds and their use as medicines | SOD CONSEILS RECH APPLIC (FR) | 2003-01-15 | — | — | CN | claimed |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | disclosed |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| CN-109810041-B | Halogenated allylamine SSAO/VAP-1 inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | AMGEN INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | AMGEN INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | COPPOLA GARY M | 2006-09-14 | — | — | US | disclosed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | disclosed |
| EP-1590319-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIEQUES (S.C.R.A.S.) | 2004-09-16 | — | — | US | disclosed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004065351-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | NOVARTIS AG (CH) | 2004-08-05 | — | — | WO | disclosed |
| US-6747024-B1 | INHIBITING CALPAIN AND/OR REACTIVE OXYGEN SPECIES IN WARM-BLOODED ANIMALS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-06-08 | — | — | US | disclosed |
| CN-1391571-A | Heterocyclic compounds and their use as medicines | SOD CONSEILS RECH APPLIC (FR) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | CAPN1, CAPN2, CAPNS1 | DHODH 3726/4885GPR119 2605/4885BRD4 1050/4885 |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | VAPB, VAPA, ADRA1D | DHODH 3059/4885GPR119 2739/4885BRD4 1545/4885 |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | HSD11B1, HSD11B2, CYP11B1 | DHODH 683/4885GPR119 33/4885BRD4 3881/4885 |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | DHODH 254/4885GPR119 3076/4885BRD4 931/4885 |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | CYP3A7, CYP51A1, NT5C3B | DHODH 150/4885GPR119 3448/4885BRD4 3281/4885 |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | HSF1, HSP90AB1, HSPB1 | DHODH 254/4885GPR119 3076/4885BRD4 931/4885 |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | DHODH 3329/4885GPR119 1019/4885BRD4 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.